Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands

Kleijburg, Anne; Braal, C. Louwrens; Westenberg, Justin D.; Jager, Agnes; Koolen, Stijn L.W.; Mathijssen, Ron H.J.; Groot, Carin A Uyl-de; Wetzelaer, Pim; Penton, Hannah

doi:10.1016/j.biopha.2022.114158

Cited by 2 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine (17%) studies reported indirect costs [ 34 , 43 , 54 – 57 , 59 – 61 ]. Productivity loss is a key indirect cost for consideration, often estimated via the human capital approach, i.e., take the patient’s perspective and count any hour not worked as an hour lost, or the friction cost approach, i.e., take the employer’s perspective and only count lost hours not worked until another employee takes over the patient’s work [ 72 ].…”

Section: Resultsmentioning

confidence: 99%

“…Stage IV) [ 38 – 40 ]: triple-negative, $34,691 vs. $176,947; HER2-positive, $34,790 vs. $134,840; HER2 negative, $21,374 vs. $90,789. Unfortunately, the studies by Brezden-Masley et al [ 38 – 40 ] did not capture indirect costs to provide a direct comparison of direct to indirect costs across cancer stages, despite other studies suggesting that indirect costs could potentially dwarf these direct costs across all cancer stages [ 1 , 34 , 43 , 54 – 57 , 59 – 61 , 73 ].…”

Section: Resultsmentioning

confidence: 99%

“…Our review also shows that drugs represent a relatively small portion of the overall economic burden of breast cancer. In comparison, indirect costs such as loss of productivity, and the financial impact associated with informal caregiving, have been shown to be relatively bigger cost drivers, when indirect costs were estimated [ 34 , 43 , 54 – 57 , 59 – 61 ]. The lack of studies estimating the indirect costs of breast cancer is concerning, given that these indirect costs can land both on the broader economy (e.g., productivity loss) but also on the person with breast cancer and their families; such aspects are an area of growing concern and consideration for policy makers.…”

Section: Discussionmentioning

confidence: 99%

“…As such, as our review indicates the high potential indirect costs associated with breast cancer, we can infer that this could lead to sex inequalities that are important considerations for policy makers. Also, our review suggests indirect costs are not currently a key focus for research projects and costing studies, perhaps because indirect costs are more difficult to quantify than direct costs; however, estimating the indirect cost burden of breast cancer is an important evidence gap identified by our review, which should be filled given the broad impact indirect costs can have on patients with breast cancer, survivors, their families, health and welfare systems, and the broader economy [ 1 , 34 , 43 , 54 – 57 , 59 – 61 , 77 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review

Franklin,

Pollard,

Sah

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Breast cancer is currently the leading cause of global cancer incidence. Breast cancer has negative consequences for society and economies internationally due to the high burden of disease which includes adverse epidemiological and economic implications. Our aim is to systematically review the estimated economic burden of breast cancer in the United States (US), Canada, Australia, and Western Europe (United Kingdom, France, Germany, Spain, Italy, Norway, Sweden, Denmark, Netherlands, and Switzerland), with an objective of discussing the policy and practice implications of our results. Methods We included English-language published studies with cost as a focal point using a primary data source to inform resource usage of women with breast cancer. We focussed on studies published since 2017, but with reported costs since 2012. A systematic search conducted on 25 January 2023 identified studies relating to the economic burden of breast cancer in the countries of interest. MEDLINE, Embase, and EconLit databases were searched via Ovid. Study quality was assessed based on three aspects: (1) validity of cost findings; (2) completeness of direct cost findings; and (3) completeness of indirect cost findings. We grouped costs based on country, cancer stage (early compared to metastatic), and four resource categories: healthcare/medical, pharmaceutical drugs, diagnosis, and indirect costs. Costs were standardized to the year 2022 in US (US$2022) and International (Int$2022) dollars. Results Fifty-three studies were included. Studies in the US ( n = 19) and Canada ( n = 9) were the majority (53%), followed by Western European countries (42%). Healthcare/medical costs were the focus for the majority (89%), followed by pharmaceutical drugs (25%), then diagnosis (17%) and indirect (17%) costs. Thirty-six (68%) included early-stage cancer costs, 17 (32%) included metastatic cancer costs, with 23% reporting costs across these cancer stages. No identified study explicitly compared costs across countries. Across cost categories, cost ranges tended to be higher in the US than any other country. Metastatic breast cancer was associated with higher costs than earlier-stage cancer. When indirect costs were accounted for, particularly in terms of productivity loss, they tended to be higher than any other estimated direct cost (e.g., diagnosis, drug, and other medical costs). Conclusion There was substantial heterogeneity both within and across countries for the identified studies’ designs and estimated costs. Despite this, current empirical literature suggests that costs associated with early initiation of treatment could be offset against potentially avoiding or reducing the overall economic burden of later-stage and more severe breast cancer. Larger scale, national, economic burden studies are needed, to be updated regularly to ensure there is an ongoing and evolving...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review

Franklin,

Pollard,

Sah

et al. 2024

Adv Ther

View full text Add to dashboard Cite

show abstract

Association of muscle strength and physical performance with the health-related quality of life of women with breast cancer

Vieira,

Mamede,

Bernabé

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To investigate the association of sarcopenia components with health-related quality of life (HRQoL) and its domains in women with breast cancer. Methods Cross-sectional study on women (30 to 80 years old) with breast cancer, with diagnosis time ≤ 12 months, without metastasis, who had not been treated for another malignancy, and without recurrences. Muscle strength, muscle mass, and physical performance were investigated by handgrip strength (HGS), appendicular skeletal muscle mass index (ASMMI), and Timed Up-and-Go test (TUGT), respectively. HRQoL and its domains were assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) and Breast Cancer-specific Core 23 (EORTC QLQ-BR23) instruments. Multiple linear regression models were conducted to verify the association between exposure and outcome variables. The significance level adopted was 5%. Results The final sample consisted of 114 women with a mean age of 55.2 ± 11.3 years. Of these, 65.8% declared themselves to be black or brown, 43.9% and 73.7% did not consume alcohol or smoke, respectively, and 70.2% were insufficiently active. For the EORTC QLQ-C30, HGS was associated with cognitive function (p = 0.047) and appetite loss (p = 0.012), while TUGT was associated with overall health (p = 0.005) and functional scale (p = 0.002). HGS and TUGT were associated with the breast cancer-specific symptoms scale (p = 0.017 and p = 0.008, respectively) of the EORTC QLQ-BR23. Conclusion Muscle strength and physical performance are associated with HRQoL domains in women with breast cancer.

show abstract

Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands

Cited by 2 publications

References 52 publications

Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review

Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review

Association of muscle strength and physical performance with the health-related quality of life of women with breast cancer

Contact Info

Product

Resources

About